Human adenovirus type 41 (HAdV-41) has the potential to be constructed as a gene transfer vector for oral vaccine or gene therapy targeting gastrointestinal tract. Block in release of progeny virus from host cell severely affects the yield during virus amplification. In this study, HAdV-5 adenovirus death protein (ADP) gene was used to replace the open reading frames (ORFs) of the HAdV-41 E3 region to construct a backbone plasmid pAdbone41ADP. Recombinant adenoviral plasmids harboring ADP and GFP genes (pAd41ADP-GFP) were generated. Plaques were formed and HAdV-41-ADP-GFP virus was rescued after transfecting pAd41ADP-GFP into the packaging cell line 293TE32. When amplified on 293TE32 cells, HAdV-41-ADP-GFP virus released to the culture medium was 10-50 times more than control virus HAdV-41-GFP, which did not carry ADP gene. The results demonstrated that incorporation of the ADP gene substantially increased the yield of recombinant HAdV-41 virus through enhancing spread of progeny virus among packaging cells.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.virusres.2013.05.003 | DOI Listing |
Int J Mol Sci
December 2024
Bioinformatics and Molecular Design Research Center (BMDRC), Incheon 21983, Republic of Korea.
Understanding drug-target interactions is crucial for identifying novel lead compounds, enhancing efficacy, and reducing toxicity. Phenotype-based approaches, like analyzing drug-induced gene expression changes, have shown effectiveness in drug discovery and precision medicine. However, experimentally determining gene expression for all relevant chemicals is impractical, limiting large-scale gene expression-based screening.
View Article and Find Full Text PDFCancer Res Treat
January 2025
Cancer Research Institute, Seoul National University, Seoul, Korea.
Purpose: This study focused on combining irinotecan with Poly (ADP-ribose) polymerase (PARP) inhibitors to explore the potential for novel combination therapeutics in small cell lung cancer (SCLC).
Materials And Methods: We selected 10 different SCLC cell lines with diverse mutational backgrounds in DNA damage response (DDR) pathway genes to evaluate the efficacy of the combination of three PARP inhibitors and irinotecan. After the cells were exposed to the drugs for seven days, cell viability was measured, and a combination index was calculated.
Bioorg Chem
December 2024
Department of Natural Products & Medicinal Chemistry, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad 500007, Telangana, India; Academy of Scientific & Innovative Research (AcSIR), Ghaziabad 201002, India. Electronic address:
Cyclin-dependent kinases, CDK7 and CDK9 play critical roles in cancer by regulating transcriptional processes essential for cell proliferation and survival. Their dysregulation leads to aberrant gene expression, promoting oncogenic pathways and contributing to tumor growth and progression. This study aimed to identify a new chemotype for CDK7/9 inhibitors using a structure-based virtual screening approach.
View Article and Find Full Text PDFJ Immunother
October 2024
Department of Radiation Oncology, Huai'an Hospital Affiliated to Xuzhou Medical University, Huai'an, China.
Colorectal cancer (CRC) ranks third globally in cancer incidence and mortality, posing a significant human concern. Recent advancements in immunotherapy are noteworthy. This study explores immune modulation for CRC treatment.
View Article and Find Full Text PDFCancer Rep (Hoboken)
January 2025
Département de Biologie, Faculté des Sciences, Université Chouaïb Doukkali, El Jadida, Morocco.
Background: The Ets-1 transcription factor plays a primordial role in regulating the expression of numerous genes implicated in cancer progression. In a previous study, we revealed that poly(ADP-ribose) polymerase-1 (PARP-1) inhibition by PJ-34 results in Ets-1 level increase in cells, which is related with cell death of Ets-1-expressing cancer cells.
Aims: The mechanism of the antitumor effect of PARP-1 inhibition was investigated in the Ets-1-expressing MDA-MB-231 breast cancer cells.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!